A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates
- 1 February 1995
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 34 (2) , 121-131
- https://doi.org/10.1016/0167-8140(95)01514-h
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetryBritish Journal of Cancer, 1993
- High activity iodine-125 interstitial implant for gliomasInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Clinical Pharmacology, Metabolism, and Tissue Distribution of 90Y-Labeled Monoclonal Antibody B72.3 After Intraperitoneal AdministrationJNCI Journal of the National Cancer Institute, 1991
- Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.Journal of Clinical Oncology, 1990
- Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitisBritish Journal of Cancer, 1990
- Monoclonal Antibodies M340 and UJ181.4 Recognize Antigens Associated with Primitive Neuroectodermal Tumours/TissuesHybridoma, 1989
- Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodiesInternational Journal of Radiation Oncology*Biology*Physics, 1989
- An analysis of dose-effect relationship in the radiotherapy of malignant gliomasInternational Journal of Radiation Oncology*Biology*Physics, 1979
- Report of Comittee II on Permissible Dose for Internal Radiation (1959)Health Physics, 1960